Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia.

Colin M McGill, Timothy J Brown, Lindsey N Fisher, Sally J Gustafson, Kriya L Dunlap, Adam J Beck, Paul T Toran, David F Claxton, Brian M Barth
{"title":"Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia.","authors":"Colin M McGill,&nbsp;Timothy J Brown,&nbsp;Lindsey N Fisher,&nbsp;Sally J Gustafson,&nbsp;Kriya L Dunlap,&nbsp;Adam J Beck,&nbsp;Paul T Toran,&nbsp;David F Claxton,&nbsp;Brian M Barth","doi":"10.31021/ijbs.20181106","DOIUrl":null,"url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy with limited treatment options. Inflammation is often a contributing factor to the development and progression of AML, and related diseases, and can potentiate therapy failure. Previously, we had identified anti-inflammatory roles and anti-AML efficacy for blueberry extracts. The present study extended these observations to determine that the polyphenol quercetin inhibited neutral sphingomyelinase (N-SMase) activity and exerted anti-AML efficacy. Moreover, quercetin was shown to exert combinatorial anti-AML efficacy with nanoliposomal ceramide. Overall, this demonstrated that quercetin could block the pro-inflammatory actions of N-SMase and augment the efficacy of anti-AML therapeutics, including ceramide-based therapeutics.</p>","PeriodicalId":87276,"journal":{"name":"International journal of biopharmaceutical sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349237/pdf/nihms959615.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of biopharmaceutical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31021/ijbs.20181106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with limited treatment options. Inflammation is often a contributing factor to the development and progression of AML, and related diseases, and can potentiate therapy failure. Previously, we had identified anti-inflammatory roles and anti-AML efficacy for blueberry extracts. The present study extended these observations to determine that the polyphenol quercetin inhibited neutral sphingomyelinase (N-SMase) activity and exerted anti-AML efficacy. Moreover, quercetin was shown to exert combinatorial anti-AML efficacy with nanoliposomal ceramide. Overall, this demonstrated that quercetin could block the pro-inflammatory actions of N-SMase and augment the efficacy of anti-AML therapeutics, including ceramide-based therapeutics.

Abstract Image

槲皮素与纳米脂质体神经酰胺联合治疗急性髓系白血病疗效观察。
急性髓性白血病(AML)是一种侵袭性血液系统恶性肿瘤,治疗方案有限。炎症通常是AML和相关疾病发生和进展的一个促成因素,并可能加剧治疗失败。此前,我们已经确定了蓝莓提取物的抗炎作用和抗aml功效。本研究扩展了这些观察结果,以确定多酚槲皮素抑制中性鞘磷脂酶(N-SMase)活性并发挥抗aml的作用。此外,槲皮素被证明与纳米脂质体神经酰胺联合抗aml。总的来说,这表明槲皮素可以阻断N-SMase的促炎作用,并增强抗aml治疗的疗效,包括基于神经酰胺的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信